Hepatocellular carcinoma treated with sorafenib

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 11-12, 2011, Pages 1347-1348

  Han, G ^a   Zhao, Y ^a   Qi, X ^a   Fan, D ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; SORAFENIB; VASCULOTROPIN;

ALBUMIN BLOOD LEVEL; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; CHILD PUGH CLASS B; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; NOTE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PYRIDINES;

EID: 81355133690     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04852.x     Document Type: Note

References (8)

1. Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-59.
2. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 391-8.
3. Qi XS, Han GH, Wu KC, et al. A confusing relationship between Child-Turcotte-Pugh Class A and compensated cirrhosis. Am J Gastroenterol 2010; 105: 470-2.
4. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
5. Verherul HM, Pinedo HM,. Possible molerular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85.
6. Je Y, Schuts FA, Choueiri TK,. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10: 967-74.
7. Tandon P, Garcia-Tsao G,. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502-10.
8. Baek KK, Kim JH, Uhm JE, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-74.